Posted by Michael Wonder on 07 Mar 2025
scPharmaceuticals announces FDA approval of supplemental new drug application expanding the Furoscix indication to include the treatment of oedema in patients with chronic kidney disease
6 March 2025 - Furoscix is expected to be available for chronic kidney disease patients in April 2025.
scPharmaceuticals today announced that the US FDA has approved the supplemental new drug application for Furoscix to expand the indication to include treatment of oedema in patients with chronic kidney disease.
